论文部分内容阅读
作者于1980年开始在塞内加尔的科尔达地区,试用一种新增效灭活脊髓灰质炎病毒疫苗(N-IPV,系一种在大病原携带者体内生长的Voro细胞上培养制备、在福尔马林中灭活的针剂疫苗,每剂含抗1、2、3型脊髓灰质炎病毒分别为40-8-32D-抗原单位)。1986～1987年脊髓灰质炎在塞内加尔全国暴发流行,借此机会作者对科尔达地区试用N-IPV的临床效果进行了配对对照研究。方法将1986年1月～1987年5月有1个或1个以上肢体发生急性麻痹,随访时(≥发病后60天)仍残留
In 1980, the authors started trial of a new active inactivated poliovirus vaccine (N-IPV, a strain of Voro that grew in large pathogen carriers) in the area of Corda in Senegal, Inactivated marclin inoculated vaccine, each containing anti-1, 2 and 3 poliovirus 40-8-32D-antigen units). Polio was endemic in Senegal from 1986 to 1987 and was used as a case-control study of the clinical efficacy of trial N-IPV in the Corda area. Methods Acute paralysis occurred in 1 or more limbs from January 1986 to May 1987 and remained at follow-up (≥60 days after onset)